ATB Therapeutics presented data supporting its “atbodies” platform—antibody-peptide fusion constructs designed to address ADC off-target toxicities and narrower therapeutic windows. At the Antibody Engineering and Therapeutics conference in Basel, co-founder and chief business officer Max Houry said the company targets a reshaped therapeutic window by using an enzymatic payload meant to be potent in small doses while reducing toxicity. The report highlights that ATB selected a catalytic payload intended not to enter untargeted healthy cells, with in vitro comparisons showing high potency against non-targeted cells for a conventional ADC reference but substantially lower toxicity at very high dosing for its atbody construct. The payload targets the ribosome, as described in the meeting materials. ATB also emphasized manufacturing considerations, saying it turned to a fusion protein approach and framed the first design question around manufacturability as much as potency.